Home › Companies › AQUESTIVE THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AQUESTIVE THERAPEUTICS INC.’s Form 8-K, filed June 11, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2025: 3 items on AQUESTIVE THERAPEUTICS INC.’s Form 8-K, filed June 11, 2025: 2 approved · 1 without a stated outcome.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AQUESTIVE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AQUESTIVE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Daniel Barber | 36,060,882 | -- | 3,546,668 | -- | 29,848,112 | — | Not verified | — |
| 2. Proposal to approve, on a non-binding advisory basis, executive compensation | 32,454,278 | 6,694,084 | 459,188 | -- | 29,848,112 | 83% | Approved | — |
| 3. Appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 | 66,530,646 | 1,166,766 | 1,758,250 | -- | -- | 98% | Approved | — |
Source: AQUESTIVE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
103 asset managers disclosed a vote on at least one AQUESTIVE THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AQUESTIVE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
98% of fund votes cast · no official result
Description as filed by funds: To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified: Daniel Barber
The 33 asset managers below reported 7,070,111 for, 109,817 withheld, 27,562 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,872,326 | 0 | 0 | 0 | For |
| BlackRock | 2,404,702 | 0 | 0 | 0 | For |
| Charles Schwab | 210,669 | 0 | 0 | 0 | For |
| Equitable | 159,281 | 0 | 0 | 0 | For |
| Goldman Sachs | 88,021 | 0 | 0 | 0 | For |
| Fidelity | 86,251 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,100 | 0 | 0 | 0 | For |
| Global X | 43,633 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 37,936 | Withhold |
| Northern Trust | 34,581 | 0 | 0 | 0 | For |
| Pacific Life | 32,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,539 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 27,562 | 0 | Abstain |
| SEI | 18,500 | 0 | 0 | 0 | For |
| Nationwide | 16,930 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 14,487 | Withhold |
| DWS | 0 | 0 | 0 | 11,740 | Withhold |
| AQR | 0 | 0 | 0 | 11,533 | Withhold |
| Brighthouse | 0 | 0 | 0 | 9,981 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 9,800 | Withhold |
| Calvert | 0 | 0 | 0 | 7,276 | Withhold |
| T. Rowe Price | 5,369 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 5,203 | Withhold |
| State Street | 3,174 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 2,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
96% of fund votes cast · no official result
Description as filed by funds: To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified: Timothy E. Morris
The 24 asset managers below reported 4,278,330 for, 194,485 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,872,326 | 0 | 0 | 0 | For |
| Equitable | 103,991 | 0 | 0 | 55,290 | Mixed |
| Goldman Sachs | 88,021 | 0 | 0 | 0 | For |
| Fidelity | 86,251 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,100 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 37,936 | Withhold |
| Northern Trust | 0 | 0 | 0 | 34,581 | Withhold |
| Pacific Life | 32,001 | 0 | 0 | 0 | For |
| Nationwide | 16,930 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 14,487 | Withhold |
| DWS | 0 | 0 | 0 | 11,740 | Withhold |
| AQR | 0 | 0 | 0 | 11,533 | Withhold |
| Brighthouse | 0 | 0 | 0 | 9,981 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 9,800 | Withhold |
| Calvert | 0 | 0 | 0 | 7,276 | Withhold |
| T. Rowe Price | 5,369 | 0 | 0 | 0 | For |
| Voya | 5,203 | 0 | 0 | 0 | For |
| State Street | 3,174 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 2,800 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,632 | 0 | 0 | 0 | For |
| TIAA | 2,367 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,165 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 1,184 | Withhold |
| Guggenheim | 0 | 0 | 0 | 677 | Withhold |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 9 asset managers below reported 2,707,113 for, 27,562 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 2,404,702 | 0 | 0 | 0 | For |
| Charles Schwab | 210,669 | 0 | 0 | 0 | For |
| Global X | 43,633 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,539 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 27,562 | 0 | Abstain |
| SEI | 18,500 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 661 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 320 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 89 | 0 | 0 | 0 | For |
Combines 7 wordings of this item as funds reported it.
83% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“2. Proposal to approve, on a non-binding advisory basis, executive compensation”): 32,454,278 for, 6,694,084 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,872,326 | 0 | 0 | 0 | For |
| BlackRock | 2,404,702 | 0 | 0 | 0 | For |
| Charles Schwab | 210,669 | 0 | 0 | 0 | For |
| Equitable | 103,991 | 55,290 | 0 | 0 | Mixed |
| Goldman Sachs | 0 | 88,021 | 0 | 0 | Against |
| Fidelity | 86,251 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,100 | 0 | 0 | 0 | For |
| Global X | 43,633 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 37,936 | 0 | 0 | Against |
| Northern Trust | 0 | 34,581 | 0 | 0 | Against |
| Pacific Life | 32,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,539 | 0 | 0 | 0 | For |
| John Hancock | 0 | 27,562 | 0 | 0 | Against |
| SEI | 18,500 | 0 | 0 | 0 | For |
| Nationwide | 16,930 | 0 | 0 | 0 | For |
| ProShares | 0 | 14,487 | 0 | 0 | Against |
| DWS | 0 | 11,740 | 0 | 0 | Against |
| AQR | 0 | 11,533 | 0 | 0 | Against |
| Brighthouse | 0 | 9,981 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 9,800 | 0 | 0 | Against |
| Calvert | 0 | 7,276 | 0 | 0 | Against |
| T. Rowe Price | 0 | 5,369 | 0 | 0 | Against |
| Voya | 0 | 5,203 | 0 | 0 | Against |
| State Street | 3,174 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 2,800 | 0 | 0 | 0 | For |
Fund voting reports, all 33 managers: 6,884,218 for, 323,272 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 2,949,266 | 0 | 0 | 0 | For |
| BlackRock | 2,171,195 | 8,082 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 1,064,760 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 920,000 | 0 | 0 | 0 | For |
| State Street | 659,696 | 4,578 | 0 | 0 | For |
| Woodline Partners LP | 401,493 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 366,116 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 363,687 | 0 | 0 | Against |
| Latash Investments, LLC | 243,134 | 0 | 0 | 0 | For |
| Charles Schwab | 210,694 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 200,000 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 158,668 | 0 | 0 | Against |
| Wellington | 149,536 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 142,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 131,564 | 0 | 0 | 0 | For |
| Citadel | 127,027 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 104,782 | 0 | 0 | Against |
| Russell Investments | 100,190 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 91,805 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 60,000 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 55,290 | 0 | 0 | Against |
| AQR | 0 | 54,605 | 0 | 0 | Against |
| Invesco | 0 | 50,655 | 0 | 0 | Against |
| Vanguard | 44,962 | 1,770 | 0 | 0 | For |
| Rhumbline | 0 | 42,655 | 0 | 0 | Against |
Institutional-manager reports, all 82 managers: 9,787,839 for, 1,454,633 against. Showing the 25 largest; every one is in the interactive database (link above).
98% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“3. Appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025”): 66,530,646 for, 1,166,766 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 7,207,490 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,872,326 | 0 | 0 | 0 | For |
| BlackRock | 2,404,702 | 0 | 0 | 0 | For |
| Charles Schwab | 210,669 | 0 | 0 | 0 | For |
| Equitable | 159,281 | 0 | 0 | 0 | For |
| Goldman Sachs | 88,021 | 0 | 0 | 0 | For |
| Fidelity | 86,251 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,100 | 0 | 0 | 0 | For |
| Global X | 43,633 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 37,936 | 0 | 0 | 0 | For |
| Northern Trust | 34,581 | 0 | 0 | 0 | For |
| Pacific Life | 32,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,539 | 0 | 0 | 0 | For |
| John Hancock | 27,562 | 0 | 0 | 0 | For |
| SEI | 18,500 | 0 | 0 | 0 | For |
| Nationwide | 16,930 | 0 | 0 | 0 | For |
| ProShares | 14,487 | 0 | 0 | 0 | For |
| DWS | 11,740 | 0 | 0 | 0 | For |
| AQR | 11,533 | 0 | 0 | 0 | For |
| Brighthouse | 9,981 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 9,800 | 0 | 0 | 0 | For |
| Calvert | 7,276 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,369 | 0 | 0 | 0 | For |
| Voya | 5,203 | 0 | 0 | 0 | For |
| State Street | 3,174 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 2,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 99,327,928 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.90% |
| 2 | BlackRock | 2.42% |
| 3 | Charles Schwab | 0.21% |
| 4 | Equitable | 0.16% |
| 5 | Goldman Sachs | 0.09% |
| 6 | Fidelity | 0.09% |
| 7 | Lincoln Financial | 0.06% |
| 8 | Global X | 0.04% |
| 9 | AIG/SunAmerica | 0.04% |
| 10 | Northern Trust | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 2.97% |
| 2 | BlackRock | 2.19% |
| 3 | Janney Montgomery Scott LLC | 1.07% |
| 4 | Blue Owl Capital Holdings LP | 0.93% |
| 5 | State Street | 0.67% |
| 6 | Woodline Partners LP | 0.40% |
| 7 | Northern Trust | 0.37% |
| 8 | STIFEL NICOLAUS & CO INC \MO\ | 0.37% |
| 9 | Latash Investments, LLC | 0.24% |
| 10 | Charles Schwab | 0.21% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BRATTON DOUGLAS K | 10,077,434 | 10.15% | Schedule 13G, filed February 13, 2025 |
| Douglas K. Bratton | 10,077,434 | 10.15% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| RTW Investments, LP | 6,250,000 | 6.29% | Schedule 13G, filed November 14, 2025 |
| BlackRock | 5,935,754 | 5.98% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 4,073,558 | 4.10% | Form 13F, quarter ended March 31, 2025 |
| MonoLine RX II, L.P. | 3,468,747 | 3.49% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Daniel Barber | 2,665,495 | 2.68% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| MonoLine RX III, L.P. | 2,657,943 | 2.68% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| MonoLine Partners, L.P. | 1,948,578 | 1.96% | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Geode Capital | 1,700,706 | 1.71% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 99,327,928 shares outstanding, as reported by AQUESTIVE THERAPEUTICS INC. on its Form 10-Q dated May 8, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AQUESTIVE THERAPEUTICS INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 103 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 467 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — AQUESTIVE THERAPEUTICS INC.'s filing reports the proposal as approved, with 83% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AQUESTIVE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AQUESTIVE THERAPEUTICS INC.’s 10-Q dated May 8, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AQUESTIVE THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AQUESTIVE THERAPEUTICS (AQST) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aquestive-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.